Duloxetine
|
|
|
- CAS-Nr.
- 116539-59-4
- Englisch Name:
- Duloxetine
- Synonyma:
- DULOXETIN;DULOXETINE HCI;DULOXETINE-D3;(S)-DULOXETINE;(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine;CS-559;DULOXETINE;(+)-Duloxetine;Duloxetine, >=99%;Duloxetine Hcl(S)
- CBNumber:
- CB8670379
- Summenformel:
- C18H19NOS
- Molgewicht:
- 297.41
- MOL-Datei:
- 116539-59-4.mol
|
Duloxetine Eigenschaften
- Siedepunkt:
- 466.2±40.0 °C(Predicted)
- Dichte
- 1.158±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- L?slichkeit
- Soluble in DMSO
- Aggregatzustand
- Oil
- pka
- 10.02±0.10(Predicted)
- Farbe
- Light brown to yellow
- BCS Class
- 2
- InChI
- InChI=1/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/s3
- InChIKey
- BFFSMCNJSOPUAY-VOPAOICTNA-N
- SMILES
- C1(=CC=CS1)[C@H](CCNC)OC1=CC=CC2=CC=CC=C12.Cl |&1:5,r|
- EPA chemische Informationen
- 2-Thiophenepropanamine, N-methyl-?-(1-naphthalenyloxy)-, (?S)- (116539-59-4)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P270 |
Bei Gebrauch nicht essen, trinken oder rauchen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P302+P352 |
BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
| P332+P313 |
Bei Hautreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P337+P313 |
Bei anhaltender Augenreizung: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen. |
| P501 |
Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen. |
|
Duloxetine Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Antidepressant.
Allgemeine Beschreibung
Duloxetine (Cymbalta) is a newer antidepressant. It islargely like venlafaxine, which is an SNERI (selective norepinephrinereuptake inhibitor).
Pharmakokinetik
Duloxetine appears to be fairly well absorbed after oral doses, with peak plasma levels in 6 to 10 hours and
linear pharmacokinetics. The drug is extensively metabolized in the liver to active
metabolites, with 72% of an oral dose primarily excreted in the urine as conjugated metabolites and up to
15% appearing in the feces.
N-demethylation to an active metabolite (CYP2D6) and hydroxylation of the naphthyl ring (CYP1A2) at either
the 4-, 5-, or 6-positions are the main metabolic pathways for duloxetine. Its metabolites are primarily
excreted into the urine as glucuronide, sulfate, and O-methylated conjugation products. The
major metabolites found in plasma also were found in the urine. Preclinical data for 4-hydroxyduloxetine
suggests it has a similar pharmacological profile to duloxetine, with selective inhibition of SERT but less
activity at the NET.
Clinical Use
Duloxetine has been approved for the treatment of depression and diabetic peripheral
neuropathic pain. It is another analogue in the line of fluoxetine-based products from Lilly, in which the phenyl and phenoxy groups of fluoxetine have been respectively replaced with the benzene isostere,
thiophene, and a
naphthyloxy group (previously described under fluoxetine). Duloxetine exhibits dual inhibition with high
affinity for the SERTs and NETs, with a five times preferential inhibition of the SERT. Duloxetine
appears to be a more potent in vitro blocker of SERTs and NETs than venlafaxine. In humans, duloxetine has
a low affinity for the other neuroreceptors, suggesting low incidence of unwanted adverse effects.
Duloxetine Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Duloxetine Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 209)Lieferanten
- methyl-[(3S)-3-(1-naphthyloxy)-3-(2-thienyl)propyl]amine
- (3R)-N-methyl-3-(naphthalen-1-yloxy)-3-thiophen-2-ylpropan-1-amine
- (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-aMine
- Duloxetine Hcl(S)
- Duloxetine, >=99%
- Methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]aMine
- DULOXETINE
- N-Methyl-gama-(1-naphthalenyloxy)-2-thiophenepropanamine
- Duloxetine & Intermediates
- 2-Thiophenepropanamine, N-methyl-γ-(1-naphthalenyloxy)-, (γS)-
- Duloxetine USP/EP/BP
- (+)-Duloxetine
- Raw Powder API Duloxetine
- DuloxetinehclQ: What is
Duloxetinehcl Q: What is the CAS Number of
Duloxetinehcl Q: What is the storage condition of
Duloxetinehcl Q: What are the applications of
Duloxetinehcl
- N-methyl-3-(1-naphthalenyloxy)-3-thiophen-2-yl-1-propanamine hydrochloride
- CS-559
- DULOXETINE-D3
- (S)-DULOXETINE
- DULOXETIN
- (3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-yl-propan-1-amine
- DULOXETINE HCI
- Duloxetine ((S)-Duloxetine
- 116539-59-4
- 1165399-59-4
- C18H18ONSHCL
- C18N19NOS
- C18H19NOS
- API
- ACTIVE PHARMACEUTICAL INGREDIENTS
